###begin article-title 0
###xml 43 44 40 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
The angiogenic response is dictated by beta3 integrin on bone marrow-derived cells
###end article-title 0
###begin p 1
###xml 37 52 37 52 <email xmlns:xlink="http://www.w3.org/1999/xlink">byzovat@ccf.org</email>
Correspondence to Tatiana V. Byzova: byzovat@ccf.org
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 137 138 133 134 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 142 143 135 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 321 322 311 312 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 466 467 453 454 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 621 622 604 605 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 626 627 606 607 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 843 844 820 821 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 425 429 <span type="species:ncbi:10090">mice</span>
###xml 558 562 <span type="species:ncbi:10090">mice</span>
Angiogenesis is dependent on the coordinated action of numerous cell types. A key adhesion molecule expressed by these cells is the alphavbeta3 integrin. Here, we show that although this receptor is present on most vascular and blood cells, the key regulatory function in tumor and wound angiogenesis is performed by beta3 integrin on bone marrow-derived cells (BMDCs) recruited to sites of neovascularization. Using knockin mice expressing functionally stunted beta3 integrin, we show that bone marrow transplantation rescues impaired angiogenesis in these mice by normalizing BMDC recruitment. We demonstrate that alphavbeta3 integrin enhances BMDC recruitment and retention at angiogenic sites by mediating cellular adhesion and transmigration of BMDCs through the endothelial monolayer but not their release from the bone niche. Thus, beta3 integrin has the potential to control processes such as tumor growth and wound healing by regulating BMDC recruitment to sites undergoing pathological and adaptive angiogenesis.
###end p 3
###begin p 4
W. Feng's present address is The First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
###end p 4
###begin p 5
Abbreviations used in this paper: BM, bone marrow; BMDC, BM-derived cell; BMT, BM transplantation; NG2, neuro/glial cell 2 chondroitin proteoglycan; SDF-1, stromal derived factor-1; SMA, smooth muscle actin; TRAcP, tartrate-resistant acid phosphatase; VE, vascular endothelium; WT, wild type.
###end p 5
###begin title 6
Introduction
###end title 6
###begin p 7
###xml 649 667 649 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">Lyden et al., 2001</xref>
###xml 669 695 669 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib58">Ziegelhoeffer et al., 2004</xref>
###xml 697 716 697 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">Peters et al., 2005</xref>
###xml 884 901 884 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib56">Yang et al., 2004</xref>
###xml 903 926 903 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">Khakoo and Finkel, 2005</xref>
###xml 928 947 928 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">Peters et al., 2005</xref>
###xml 949 971 949 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Grunewald et al., 2006</xref>
###xml 973 989 973 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">Jin et al., 2006</xref>
###xml 1158 1184 1158 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib58">Ziegelhoeffer et al., 2004</xref>
###xml 1186 1208 1186 1208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Grunewald et al., 2006</xref>
###xml 1210 1227 1210 1227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">Ruiz et al., 2006</xref>
Angiogenesis, the formation of new blood vessels from existing vasculature, is crucial for many physiological and pathological processes including, but not limited to, fetal development, tissue repair, and tumor growth. Originally, angiogenesis was believed to primarily rely on the expansion of local vascular endothelial (VE) cells; however, the process is much more complicated and involves coordination of vascular cells with fibroblasts, immune cells of blood and tissue origin, and circulating blood components. Numerous studies have demonstrated the involvement of recruited bone marrow (BM)-derived cells (BMDCs) in neovascular development (Lyden et al., 2001; Ziegelhoeffer et al., 2004; Peters et al., 2005). Although the identity and origin of these cells remains unclear and somewhat controversial, a role for BMDCs in angiogenesis has been documented by multiple groups (Yang et al., 2004; Khakoo and Finkel, 2005; Peters et al., 2005; Grunewald et al., 2006; Jin et al., 2006). These BMDCs appear to promote angiogenesis through the release of proangiogenic factors at sites of neovascularization to stimulate expansion of local blood vessels (Ziegelhoeffer et al., 2004; Grunewald et al., 2006; Ruiz et al., 2006). Despite growing evidence depicting a key regulatory role of these cells in angiogenesis, the mechanisms underlying BMDC release, recruitment, and retention at sites of neovascularization are just now beginning to be investigated.
###end p 7
###begin p 8
###xml 134 160 134 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">Eliceiri and Cheresh, 2001</xref>
###xml 162 188 162 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">Mahabeleshwar et al., 2007</xref>
###xml 456 457 452 453 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 461 462 454 455 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 464 479 457 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">Carmeliet, 2002</xref>
###xml 571 572 560 561 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 576 577 562 563 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 595 616 581 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">Reynolds et al., 2002</xref>
###xml 618 622 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">2004</xref>
###xml 624 650 610 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">Mahabeleshwar et al., 2006</xref>
###xml 746 747 729 730 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 918 938 901 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib52">Umemoto et al., 2006</xref>
As in leukocyte adhesion and trafficking, specific key steps of BMDC recruitment are potentially mediated by cell adhesion molecules (Eliceiri and Cheresh, 2001; Mahabeleshwar et al., 2007). The primary class of receptors known to mediate cell adhesion to other cells and extracellular matrix are integrins. Although many integrins have been shown to be involved in various aspects of angiogenesis, one of the most intriguing players remains integrin alphavbeta3 (Carmeliet, 2002). The vast majority of studies have focused on the regulatory function of endothelial alphavbeta3 in angiogenesis (Reynolds et al., 2002, 2004; Mahabeleshwar et al., 2006); however, this receptor is also present on a variety of BMDCs. It has been suggested that beta3 integrin is a common surface marker for tissue-specific stem cells and its expression was found to be correlated to the properties of quiescent hematopoietic stem cells (Umemoto et al., 2006).
###end p 8
###begin p 9
###xml 42 43 39 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 139 140 129 130 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 210 211 197 198 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 236 256 223 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">Brooks et al., 1994a</xref>
###xml 257 258 244 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">b</xref>
###xml 260 286 247 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">Eliceiri and Cheresh, 1999</xref>
###xml 288 292 275 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">2001</xref>
###xml 294 315 281 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">Reynolds et al., 2002</xref>
###xml 317 337 304 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib51">Taverna et al., 2004</xref>
###xml 339 365 326 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">Mahabeleshwar et al., 2006</xref>
###xml 367 384 354 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib55">Weis et al., 2007</xref>
###xml 425 426 409 410 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 519 520 499 500 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 524 525 501 502 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 562 583 539 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">Kanamori et al., 2006</xref>
###xml 585 602 562 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib55">Weis et al., 2007</xref>
###xml 687 688 661 662 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 230 234 <span type="species:ncbi:10090">mice</span>
###xml 445 449 <span type="species:ncbi:10090">mice</span>
One of the most intriguing aspects of beta3 integrin function in angiogenesis is the reported discrepancy between the effects of alphavbeta3 inhibitors on pathological angiogenesis and the phenotype of the beta3 integrin knockout mice (Brooks et al., 1994a,b; Eliceiri and Cheresh, 1999, 2001; Reynolds et al., 2002; Taverna et al., 2004; Mahabeleshwar et al., 2006; Weis et al., 2007). Importantly, recent studies using beta3 integrin knockout mice clearly demonstrate not suppressing but the stimulatory role of alphavbeta3 on angiogenesis in certain tissues (Kanamori et al., 2006; Weis et al., 2007). These studies further emphasize the need to solidify the very complex role of beta3 integrins in the regulation of physiological and pathological neovascularization.
###end p 9
###begin p 10
###xml 26 27 22 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 31 32 24 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 121 147 114 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">De Nichilo and Burns, 1993</xref>
###xml 238 260 231 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Grunewald et al., 2006</xref>
###xml 262 279 255 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">Ruiz et al., 2006</xref>
###xml 510 523 503 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">Epstein, 2004</xref>
###xml 525 547 518 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">Burger and Kipps, 2006</xref>
###xml 549 566 542 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">Ruiz et al., 2006</xref>
###xml 793 811 786 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">Orimo et al., 2005</xref>
###xml 813 835 806 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Grunewald et al., 2006</xref>
Expression levels of alphavbeta3 on the surface of myeloid cells were shown to be regulated by cytokines and chemokines (De Nichilo and Burns, 1993). Cytokines and chemokines also play vital roles in the mobilization and homing of BMDCs (Grunewald et al., 2006; Ruiz et al., 2006). Stromal derived factor-1 (SDF-1), a CXC chemokine family member, controls numerous homeostatic, developmental, and pathological processes through interaction with its cognate receptor, CXCR4, which is highly expressed by BMDCs (Epstein, 2004; Burger and Kipps, 2006; Ruiz et al., 2006). Emerging evidence indicates that the SDF-1/CXCR4 axis plays a pivotal role in the mobilization of hematopoietic cells from BM into peripheral blood and in dictating positional engraftment of these cells at angiogenic sites (Orimo et al., 2005; Grunewald et al., 2006).
###end p 10
###begin p 11
###xml 52 73 52 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">De Palma et al., 2005</xref>
###xml 75 97 75 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Grunewald et al., 2006</xref>
###xml 126 127 123 124 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 173 195 170 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">Chandhoke et al., 2004</xref>
###xml 197 223 194 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">Mahabeleshwar et al., 2006</xref>
###xml 225 245 222 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib52">Umemoto et al., 2006</xref>
###xml 299 300 293 294 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 336 356 330 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">Brooks et al., 1994a</xref>
###xml 358 384 352 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">Eliceiri and Cheresh, 1999</xref>
###xml 386 407 380 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">Reynolds et al., 2002</xref>
###xml 409 429 403 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib51">Taverna et al., 2004</xref>
###xml 431 452 425 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">Kanamori et al., 2006</xref>
###xml 626 627 617 618 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 761 762 749 750 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 810 811 795 796 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 920 946 905 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">Mahabeleshwar et al., 2006</xref>
###xml 1226 1227 1207 1208 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 1231 1232 1209 1210 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1274 1295 1252 1273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">Blystone et al., 1997</xref>
###xml 1297 1319 1275 1297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">Chandhoke et al., 2004</xref>
###xml 1631 1632 1606 1607 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1740 1741 1711 1712 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 1745 1746 1713 1714 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 596 600 <span type="species:ncbi:10090">mice</span>
###xml 607 611 <span type="species:ncbi:10090">mice</span>
###xml 780 784 <span type="species:ncbi:10090">mice</span>
###xml 1492 1496 <span type="species:ncbi:10090">mice</span>
###xml 1519 1523 <span type="species:ncbi:10090">mice</span>
###xml 1544 1559 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1579 1583 <span type="species:ncbi:10090">mice</span>
The importance of BMDCs in neovascular development (De Palma et al., 2005; Grunewald et al., 2006), the unique pattern of beta3 integrin expression and cellular regulation (Chandhoke et al., 2004; Mahabeleshwar et al., 2006; Umemoto et al., 2006), and the intriguing, yet controversial, role of beta3 integrin receptor in angiogenesis (Brooks et al., 1994a; Eliceiri and Cheresh, 1999; Reynolds et al., 2002; Taverna et al., 2004; Kanamori et al., 2006) has prompted us to focus on the role of this integrin in the biology of BMDCs in angiogenesis. As a basic experimental model, we used knockin mice (DiYF mice) in which beta3 integrin tyrosines 747 and 759 are mutated to phenylalanine. We have previously shown that defective tyrosine phosphorylation of beta3 integrin in DiYF mice resulted in abnormal beta3 function denoted by impaired endothelial cell adhesion, spreading, migration, and tumor angiogenic defects (Mahabeleshwar et al., 2006). This mutation is not limited to endothelial cells but affects numerous cell types involved in the regulation of angiogenesis, including platelets, leukocytes, and, potentially, other BMDCs. Previous in vitro studies have indicated that Y747 phosphorylation is crucial for alphavbeta3 integrin function on myeloid cell lines (Blystone et al., 1997; Chandhoke et al., 2004). The present study is based on our surprising initial finding that transplantation of wild-type (WT) BM completely rescues angiogenic defects in tumors and wounds of DiYF mice. We have crossed DiYF mice with GFP-expressing transgenic mice to create DiYF/GFP mice as a source of BM to delineate the role of beta3 integrin in the release and recruitment of BMDCs to sites of angiogenesis. Our analysis revealed that alphavbeta3 integrin on BMDCs plays a key role in tumor associated pathological angiogenesis as well as in wounds via regulation of BMDC adhesion and transmigration into sites of neovascularization, but not their release from the bone niche.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
###xml 80 84 <span type="species:ncbi:10090">mice</span>
BM transplantation (BMT) restores normal tumor growth and wound healing in DiYF mice
###end title 13
###begin p 14
###xml 146 147 143 144 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
We have previously shown that endothelial cell function and angiogenesis are impaired in DiYF mice. In this study, we investigate the role of beta3 integrin in BMDC recruitment to sites of neovascularization. To this end, we performed a series of BMT and assessed the role of BM in angiogenesis-dependent responses, i.e., tumor growth and wound healing.
###end p 14
###begin p 15
###xml 38 64 38 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">Mahabeleshwar et al., 2006</xref>
###xml 322 330 318 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 408 416 404 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 727 728 718 719 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 141 145 <span type="species:ncbi:10090">mice</span>
###xml 287 291 <span type="species:ncbi:10090">mice</span>
###xml 371 377 <span type="species:ncbi:10090">murine</span>
###xml 588 592 <span type="species:ncbi:10090">mice</span>
###xml 666 670 <span type="species:ncbi:10090">mice</span>
In accord with our previous findings (Mahabeleshwar et al., 2006), the growth of implanted B16F10 melanoma was reduced about twofold in DiYF mice compared with WT counterparts. Transplantation of WT BM into irradiated DiYF hosts (WT-->DiYF) normalized tumor growth to that of control WT mice receiving WT marrow (WT-->WT; Fig. 1 A). These results were corroborated using murine RM1 prostate carcinoma cells (Fig. 1 B). Alternatively, transplantation of DiYF BM into irradiated WT hosts (DiYF-->WT) resulted in stunted B16F10 and RM1 tumor growth, a difference similar to that observed in mice not undergoing BMT. These data suggest that reduced tumor growth in DiYF mice is at least partially a consequence of altered BMDC beta3 integrin function.
###end p 15
###begin p 16
###xml 0 77 0 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Reduced tumor growth and delayed wound healing in DiYF mice are BM dependent.</bold>
###xml 255 256 253 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 538 539 534 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 566 567 562 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 993 994 987 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1020 1021 1012 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1039 1040 1029 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 55 59 <span type="species:ncbi:10090">mice</span>
###xml 135 139 <span type="species:ncbi:10090">mice</span>
###xml 169 173 <span type="species:ncbi:10090">mice</span>
###xml 328 332 <span type="species:ncbi:10090">mice</span>
###xml 361 365 <span type="species:ncbi:10090">mice</span>
###xml 630 634 <span type="species:ncbi:10090">mice</span>
###xml 745 749 <span type="species:ncbi:10090">mice</span>
###xml 882 886 <span type="species:ncbi:10090">mice</span>
###xml 915 919 <span type="species:ncbi:10090">mice</span>
Reduced tumor growth and delayed wound healing in DiYF mice are BM dependent. (A) Weights of subcutaneous B16F10 tumors in WT and DiYF mice (11 d after implantation) or mice undergoing BMT (13 d) with WT or DiYF donor marrow. Data represent mean +/- SEM (n = 10 per group). (B) Weights of subcutaneous RM1 tumors in WT and DiYF mice (9 d after implantation) or mice undergoing BMT with WT donor marrow (11 d after implantation). Representative tumors are depicted above their respective dataset. Data represent mean +/- SEM (without BMT, n = 14 per group; with BMT, n = 18 per group). (C) Analysis of wound healing in WT and DiYF mice. Gross visualization of healing wounds 3 (top left) and 7 (bottom left) d after wound creation in WT and DiYF mice not undergoing (top left) and undergoing (bottom left) BMT with WT or DiYF donor marrow. Percentage of wound closure in WT and DiYF mice (top right) and WT and DiYF mice (bottom right) undergoing BMT. Data represent mean +/- SEM (WT and DiYF, n = 10 per group; WT-->WT, n = 16; WT-->DiYF, n = 12). *, P < 0.05.
###end p 16
###begin p 17
###xml 277 285 277 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 504 512 504 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 822 823 819 820 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 166 170 <span type="species:ncbi:10090">mice</span>
###xml 324 328 <span type="species:ncbi:10090">mice</span>
###xml 411 415 <span type="species:ncbi:10090">mice</span>
###xml 487 491 <span type="species:ncbi:10090">mice</span>
###xml 656 660 <span type="species:ncbi:10090">mice</span>
###xml 784 788 <span type="species:ncbi:10090">mice</span>
To illustrate that the observed BMT angiogenic rescue effect wasn't specific to our tumor model, we examined wound healing. By analyzing wound closure, we found diYF mice displayed an early (3-7 d) wound healing delay (extent of closure) and extended time to complete closure (Fig. 1 C, top). Whereas reconstitution of DiYF mice with WT BM restored the wound healing process, transplantation of DiYF BM into WT mice reduced the extent of wound closure 3 d after surgery compared with WT mice with WT BM (Fig. 1 C, bottom). Gross inspection of healing wounds illuminated an angiogenic defect as the potential causative factor in the delay exhibited by DiYF mice, a condition corrected by BMT with WT marrow. These data demonstrated that impaired tumor growth and wound healing in DiYF mice are a consequence of altered beta3 integrin function of BMDCs and not of local remodeling tissues and that BM reconstitution may reverse such angiogenic defects.
###end p 17
###begin title 18
###xml 40 44 <span type="species:ncbi:10090">mice</span>
DiYF angiogenic defects are reversed in mice transplanted with normal BM
###end title 18
###begin p 19
###xml 80 106 80 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">Mahabeleshwar et al., 2006</xref>
###xml 629 637 629 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 1332 1340 1332 1340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 1433 1441 1433 1441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 C</xref>
###xml 1615 1641 1615 1641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">Mahabeleshwar et al., 2006</xref>
###xml 1703 1711 1703 1711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 C</xref>
###xml 74 78 <span type="species:ncbi:10090">mice</span>
###xml 1326 1330 <span type="species:ncbi:10090">mice</span>
###xml 1480 1484 <span type="species:ncbi:10090">mice</span>
###xml 1516 1520 <span type="species:ncbi:10090">mice</span>
###xml 1697 1701 <span type="species:ncbi:10090">mice</span>
###xml 1834 1838 <span type="species:ncbi:10090">mice</span>
Having previously reported angiogenic defects in implanted tumors of DiYF mice (Mahabeleshwar et al., 2006), we further investigated the phenotype of these defects and whether they were BM dependent. Histological examination of B16F10 and RM1 tumor, as well as wound sections, illuminates this angiogenic defect (Fig. S1 A, available at ). Double staining of B16F10 tumor sections with the endothelial cell marker CD31 and the pericyte marker neuro/glial cell 2 chondroitin proteoglycan (NG2) revealed a substantial (greater than threefold) decrease in both CD31- and NG2-positive blood vessel densities in tumors of DiYF hosts (Fig. 2 A). Total VE cell and pericytes positive areas in tumor tissues were also decreased (by 55 and 45%, respectively) in DiYF hosts (Fig. S1 B, top left) with no accompanying differences in blood vessel size (Fig. S1 B, top right). Colocalization of endothelial cells and pericytes in tumor vasculature revealed no morphological differences between B16F10 tumor sections regardless of host genotype. A reduction in the basement membrane protein laminin was also evident in tumors of DiYF hosts (Fig. S1 B, middle left). In addition, smooth muscle actin (SMA), a myofibroblast and adult smooth muscle pericyte marker, exhibited a fourfold decrease in DiYF B16F10 tumor sections compared with WT mice (Fig. 2 B). Immunohistochemical analysis revealed a decrease in von Willebrand factor vessel density (Fig. 2 C) and area (Fig. S1 B, bottom) in DiYF mice wound tissues compared with WT mice. Reduced staining for these vascular markers has previously been shown in RM1 tumor sections (Mahabeleshwar et al., 2006) and is consistent with that of healing wounds of DiYF mice (Fig. 2 C and Fig. S1 B, middle right) as well. These data illustrate the angiogenic defects of implanted tumors and wounds of DiYF mice.
###end p 19
###begin p 20
###xml 0 54 0 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The angiogenic phenotype of DiYF mice is BM dependent.</bold>
###xml 33 37 <span type="species:ncbi:10090">mice</span>
###xml 159 163 <span type="species:ncbi:10090">mice</span>
###xml 226 230 <span type="species:ncbi:10090">mice</span>
###xml 376 380 <span type="species:ncbi:10090">mice</span>
###xml 540 544 <span type="species:ncbi:10090">mice</span>
###xml 692 696 <span type="species:ncbi:10090">mice</span>
###xml 877 881 <span type="species:ncbi:10090">mice</span>
###xml 1013 1017 <span type="species:ncbi:10090">mice</span>
###xml 1174 1178 <span type="species:ncbi:10090">mice</span>
###xml 1295 1299 <span type="species:ncbi:10090">mice</span>
###xml 1443 1447 <span type="species:ncbi:10090">mice</span>
The angiogenic phenotype of DiYF mice is BM dependent. (A) Immunofluorescent detection of CD31 (red) and NG2 (green) in B16F10 tumor sections from WT and DiYF mice (left). Microvessel density in B16F10 tumors from WT and DiYF mice (right). Bar, 100 mum. Data represent mean +/- SEM. **, P < 0.01. (B) SMA-positive microvessel density of B16F10 tumor sections from WT and DiYF mice. Data represent mean +/- SEM. *, P < 0.05. (C) von Willebrand factor (vWF)-positive microvessel density of tissue sections from 10-d-old wounds of WT and DiYF mice. Data represent mean +/- SEM. *, P < 0.05. (D) Immunofluorescent detection of CD31 (red) and NG2 (green) in B16F10 tumor sections from WT and DiYF mice after BMT with WT donor marrow (left). Bar, 200 mum. Insets depict similarities in vessel cellular organization. CD31 and NG2 microvessel density in B16F10 tumors from WT and DiYF mice after BMT with WT donor marrow (right). Data represent mean +/- SEM. (E) SMA microvessel density in B16F10 tumors from WT and DiYF mice after BMT with WT donor marrow. Data represent mean +/- SEM. (F) Immunofluorescent detection of CD31 (red) and NG2 (green) in B16F10 tumor sections from WT mice after BMT with WT or DiYF donor marrow (left). Bar, 200 mum. CD31 and NG2 microvessel area in B16F10 tumors from WT mice after BMT with WT or DiYF donor marrow (right). Data represent mean +/- SEM. *, P < 0.05. (G) SMA microvessel density in B16F10 tumors from WT mice after BMT with WT and DiYF donor marrow. Data represent mean +/- SEM. *; P < 0.05.
###end p 20
###begin p 21
###xml 289 297 289 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 D</xref>
###xml 453 461 453 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 E</xref>
###xml 838 846 838 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 F</xref>
###xml 969 977 965 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 G</xref>
###xml 1106 1107 1099 1100 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 396 400 <span type="species:ncbi:10090">mice</span>
###xml 427 431 <span type="species:ncbi:10090">mice</span>
###xml 615 619 <span type="species:ncbi:10090">mice</span>
###xml 741 745 <span type="species:ncbi:10090">mice</span>
###xml 816 820 <span type="species:ncbi:10090">mice</span>
###xml 910 914 <span type="species:ncbi:10090">mice</span>
###xml 963 967 <span type="species:ncbi:10090">mice</span>
###xml 1021 1025 <span type="species:ncbi:10090">mice</span>
Histological examination of B16F10 and RM1 tumor sections from DiYF hosts undergoing BMT with WT donor marrow revealed a possible restoration of angiogenesis (Fig. S1 C). This was confirmed immunohistochemically by double staining B16F10 tumor sections with anti-CD31 and -NG2 antibodies (Fig. 2 D and Fig. S1 D). The density of SMA-positive vessels in tumor sections of WT marrow recipient DiYF mice was similar to that of WT mice receiving WT marrow (Fig. 2 E). Conversely, we performed BMT wherein WT BM was reconstituted with DiYF marrow. Although immunohistochemical analysis of B16F10 tumor sections in these mice revealed no statistically significant difference in blood vessel density (Fig. S1 E), transplantation of DiYF BM into WT mice caused a reduction in blood vessel and pericyte area compared with WT mice receiving WT BM (Fig. 2 F). SMA-positive vessel densities in tumor sections of DiYF-->WT mice were also reduced by >40% compared with WT-->WT mice (Fig. 2 G). Thus, transplantation of DiYF BM into WT mice yields tumor angiogenic defects as well. These data therefore indicate that beta3 integrin function of BM cells plays a key role in angiogenesis.
###end p 21
###begin title 22
Platelet defects are not causative in the DiYF angiogenic defect
###end title 22
###begin p 23
###xml 39 42 35 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink">IIb</sub>
###xml 46 47 39 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 92 108 85 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">Law et al., 1999</xref>
###xml 745 746 718 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 866 867 835 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 225 229 <span type="species:ncbi:10090">mice</span>
###xml 245 250 <span type="species:ncbi:10090">mouse</span>
###xml 315 319 <span type="species:ncbi:10090">mice</span>
###xml 594 598 <span type="species:ncbi:10090">mice</span>
###xml 821 825 <span type="species:ncbi:10090">mice</span>
###xml 1020 1024 <span type="species:ncbi:10090">mice</span>
###xml 1123 1127 <span type="species:ncbi:10090">mice</span>
###xml 1314 1318 <span type="species:ncbi:10090">mice</span>
Because the DiYF mutation affects alphaIIbbeta3 signaling and platelet-dependent responses (Law et al., 1999), we next assessed to what extent, if any, that platelets contribute to the abnormal angiogenesis exhibited by DiYF mice. Using an anti-mouse GPIbalpha antibody, platelets were depleted in both WT and DiYF mice causing a >90% reduction in circulating platelets compared with control IgG. This reduced platelet level was maintained during the entire experiment through repeated antibody treatment. Although platelet depletion resulted in a reduction of tumor growth in both WT and DIYF mice, tumors in platelet-depleted WT hosts were approximately70% larger than those formed in DiYF counterparts (0.323 +/- 0.034 vs. 0.191 +/- 0.051 g, n = 10, P < 0.05), a difference paralleling that of nondepleted WT and DiYF mice (0.493 +/- 0.051 vs. 0.346 +/- 0.046 g, n = 10, P < 0.05). Immunohistochemical analysis of tumor sections with laminin revealed that the difference in tumor vascular density between WT and DiYF mice remained after platelet depletion (unpublished data), a difference similar to that of WT and DiYF mice. Thus, although platelets are indeed important for tumor progression and angiogenesis, impaired platelet function is not the predominant contributor to altered tumor progression in DiYF mice.
###end p 23
###begin title 24
Recruitment of DiYF BMDCs to sites of neovascularization is impaired
###end title 24
###begin p 25
###xml 53 57 <span type="species:ncbi:10090">mice</span>
###xml 160 164 <span type="species:ncbi:10090">mice</span>
###xml 214 218 <span type="species:ncbi:10090">mice</span>
###xml 275 279 <span type="species:ncbi:10090">mice</span>
###xml 322 326 <span type="species:ncbi:10090">mice</span>
###xml 417 421 <span type="species:ncbi:10090">mice</span>
###xml 445 449 <span type="species:ncbi:10090">mice</span>
Because BMT rescued the angiogenic phenotype of DiYF mice, we next assessed whether recruitment of BMDCs into the developing vasculature was defective in these mice. To monitor the extent of BMDC recruitment, DiYF mice were crossed with GFP-expressing transgenic WT (WT/GFP) mice. The resultant DiYF/GFP and normal WT/GFP mice were used as donors for BMT experiments. In brief, WT/GFP marrow was transplanted into WT mice (WT/GFP-->WT) and DiYF mice (WT/GFP-->DiYF) and WT marrow was reconstituted with donor DiYF/GFP marrow (DiYF/GFP-->WT). More than 80% of nucleated cells and 95% of platelets in blood expressed GFP 8 wk after BMT.
###end p 25
###begin p 26
###xml 79 80 79 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 164 172 164 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 178 179 178 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 386 387 380 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 445 453 435 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 735 743 725 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 950 951 940 941 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1077 1085 1065 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 C</xref>
###xml 1155 1156 1143 1144 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1338 1339 1319 1320 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 45 49 <span type="species:ncbi:10090">mice</span>
###xml 240 244 <span type="species:ncbi:10090">mice</span>
###xml 284 288 <span type="species:ncbi:10090">mice</span>
###xml 439 443 <span type="species:ncbi:10090">mice</span>
###xml 595 599 <span type="species:ncbi:10090">mice</span>
###xml 898 902 <span type="species:ncbi:10090">mice</span>
###xml 1005 1009 <span type="species:ncbi:10090">mice</span>
###xml 1024 1028 <span type="species:ncbi:10090">mice</span>
###xml 1213 1217 <span type="species:ncbi:10090">mice</span>
Analysis of B16F10 tumors formed in chimeric mice revealed large numbers of GFP+ cells located within the tumor periphery and in the vicinity of tumor vasculature (Fig. 3 A). GFP+ cell numbers were elevated in WT/GFP-->WT and WT/GFP-->DiYF mice compared with those from DiYF/GFP-->WT mice (Fig. S2, available at ). Importantly, there was no significant difference in the presence of GFP+ cells in tumors from WT/GFP-->WT and WT/GFP-->DiYF mice (Fig. 3 B), indicating that recruitment of BMDCs and not host vasculature deficiencies are responsible for the impaired angiogenesis exhibited by DiYF mice. These findings were confirmed by assessing infiltration of BMDCs into healing wounds 7 d after wound initiation. As shown previously (Fig. 1 C, bottom right), histological analysis of wound tissues at this time point revealed almost complete wound closure and vascular similarities in WT and DiFY mice. Similar to our tumor model, recruitment of GFP+ cells to wound tissues was impaired in DiYF/GFP-->WT mice compared with mice receiving WT/GFP marrow regardless of genotype (Fig. 3 C). In fact, there was no significant difference in the presence of GFP+ cells in wound tissues of WT/GFP-->WT and WT/GFP-->DiYF mice. Results of our tumor and wound studies emphasize the importance of BMDCs in angiogenic processes and indicate that beta3 integrin function is essential for BMDC recruitment to sites of neovascularization.
###end p 26
###begin p 27
###xml 29 30 26 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 0 50 0 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Infiltration of BMDCs is &#946;<sub>3</sub> integrin dependent.</bold>
###xml 142 146 <span type="species:ncbi:10090">mice</span>
###xml 292 296 <span type="species:ncbi:10090">mice</span>
###xml 492 496 <span type="species:ncbi:10090">mice</span>
Infiltration of BMDCs is beta3 integrin dependent. (A) Immunofluorescent detection of SMA (red) and GFP (green) on B16F10 tumor tissues in WT mice after BMT with WT/GFP or DiYF/GFP donor marrow. Bar, 100 mum. (B) Quantification of GFP-positive cells in B16F10 tumor sections from WT and DiYF mice after BMT with WT/GFP or DiYF/GFP donor marrow. Data represent mean +/- SEM. *, P < 0.05; **, P < 0.01. (C) Quantification of GFP-positive cells in wound tissue (day 7) sections from WT and DiYF mice after BMT with WT/GFP or DiYF/GFP donor marrow. Data represent mean +/- SEM. *, P < 0.05; **, P < 0.01.
###end p 27
###begin title 28
The majority of tumor-infiltrating BMDCs are of hematopoietic origin
###end title 28
###begin p 29
###xml 458 466 452 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 571 579 565 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 605 613 599 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 C</xref>
###xml 1293 1315 1275 1297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Grunewald et al., 2006</xref>
###xml 1317 1337 1299 1319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib49">Shojaei et al., 2007</xref>
###xml 1339 1343 1321 1325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib50">2008</xref>
###xml 1345 1366 1327 1348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">Purhonen et al., 2008</xref>
###xml 1569 1590 1551 1572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">Purhonen et al., 2008</xref>
###xml 1749 1769 1731 1751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib49">Shojaei et al., 2007</xref>
###xml 1771 1775 1753 1757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib50">2008</xref>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
The localization of BMDCs in tumor neovasculature of DiYF/GFP-->WT, WT/GFP-->WT, and WT/GFP-->DiYF mice was examined by double staining of tumor sections for GFP (to visualize recruited BMDCs) and CD31 or VE-Cadherin (endothelium markers), laminin (blood vessel basement membrane), or SMA. BMDCs were prominent in the vicinity of blood vessels of B16F10 and RM1 tumors but were distinctly separate from the endothelial lining stained by CD31 or VE-Cadherin (Fig. 4 A and Fig. S3 B, available at ). GFP-positive cells were situated adjacent to both the basement membrane (Fig. 4 B) and SMA-positive cells (Fig. 4 C). Western analysis of B16 F10 tumor lysates (WT/GFP-->WT and DiYF/GFP-->WT) showed decreased expression levels of GFP in tumors with DiYF/GFP-->WT compared with WT/GFP-->WT (Fig. S3, C and D). Additionally, Western analysis of DiYF/GFP-->WT also exhibited reduced expression levels of VE-Cadherin and CD31 compared with WT/GFP-->WT (Fig. S3, C and D). Our results indicate that although BMDCs did not directly incorporate into the tumor neovasculature, they are situated in close proximity to blood vessels and might affect angiogenesis by secreting key effectors. This is further supported by several other studies emphasizing the role of promyeloid cells in tumor vasculature (Grunewald et al., 2006; Shojaei et al., 2007, 2008; Purhonen et al., 2008). These groups demonstrated that BMDCs do not incorporate into endothelium. A recent study using B16 melanoma clearly shows the lack of markers such as CD31, von Willebrand factor, and VEGFR2 on BMDCs (Purhonen et al., 2008). Moreover, several comprehensive studies conclusively show that it is the population of myeloid cells from BM that makes all the difference in tumor growth (Shojaei et al., 2007, 2008).
###end p 29
###begin p 30
###xml 0 68 0 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Localization of BMDCs in the area of blood vessels in tumor tissues.</bold>
###xml 196 200 <span type="species:ncbi:10090">mice</span>
###xml 369 373 <span type="species:ncbi:10090">mice</span>
###xml 527 531 <span type="species:ncbi:10090">mice</span>
Localization of BMDCs in the area of blood vessels in tumor tissues. (A) Immunofluorescent detection of CD31 (red) and GFP (green) in B16F10 (top) and RM1 (bottom) tumor sections from WT and DiYF mice after BMT with WT/GFP or DiYF/GFP donor marrow. Bar, 50 mum. (B) Immunofluorescent detection of laminin (red) and GFP (green) in B16F10 tumor sections from WT and DiYF mice after BMT with WT/GFP donor marrow. Bar, 100 mum. (C) Immunofluorescent detection of SMA (red) and GFP (green) in B16F10 tumor sections from WT and DiYF mice after BMT with WT/GFP or DiYF/GFP donor marrow. Bar, 100 mum.
###end p 30
###begin p 31
###xml 161 187 161 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib58">Ziegelhoeffer et al., 2004</xref>
###xml 401 402 401 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 440 448 440 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 472 473 472 473 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 477 478 477 478 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 616 617 609 610 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 663 664 656 657 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 518 522 <span type="species:ncbi:10090">mice</span>
###xml 568 572 <span type="species:ncbi:10090">mice</span>
Studies using models of ischemia have shown that the majority of BMDCs recruited to sites of insult are leukocytes, macrophages, T lymphocytes, and fibroblasts (Ziegelhoeffer et al., 2004). By costaining B16F10 tumor sections for GFP and CD45, a marker for leukocytes or hematopoietic cells, including hematopoietic progenitor/stem cells except erythrocytes and platelets, we found that BM-derived GFP+ cells were frequently CD45 positive (Fig. 5 A) with the extent of GFP+CD45+ double positive cells in DiYF/GFP-->WT mice reduced in comparison to that of WT/GFP-->WT mice. This alludes to an essential role for beta3 integrin signaling in the recruitment of CD45+ cells from BM into sites of angiogenesis.
###end p 31
###begin p 32
###xml 0 43 0 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Identification of tumor infiltrating BMDCs.</bold>
###xml 191 195 <span type="species:ncbi:10090">mice</span>
###xml 352 356 <span type="species:ncbi:10090">mice</span>
###xml 685 689 <span type="species:ncbi:10090">mice</span>
Identification of tumor infiltrating BMDCs. (A) Immunofluorescent detection of GFP (a and d) and CD45 (Ab and Ae) along with the merged image (Ac and Af). Sections are of B16F10 origin in WT mice after BMT with WT/GFP (a-c) or DiYF/GFP (d-f) donor marrow. (B) Immunofluorescent detection of GFP (green) and F4/80 (red) in B16F10 tumor sections from WT mice after BMT with WT/GFP (a) or DiYF/GFP (c) donor marrow. Blood vessels marked as V. (b and d) Higher magnifications of enclosed boxes in a and c, respectively. (C) Immunofluorescent detection of CD45+F4/80+Gr-1+CD3 (a and e) and GFP (b and f) along with merged images of B16F10 (c and g) and RM1 (d and h) tumor sections from WT mice after BMT with WT/GFP (a-c) or DiYF/GFP (e-h) donor marrow. Arrows indicate GFP-positive cells that are negative for CD45+F4/80+Gr-1+CD3. Bars, 100 mum.
###end p 32
###begin p 33
###xml 19 20 19 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 298 299 298 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 307 308 307 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 364 372 364 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 B</xref>
###xml 896 897 892 893 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 993 1001 989 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 202 206 <span type="species:ncbi:10090">mice</span>
###xml 225 229 <span type="species:ncbi:10090">mice</span>
###xml 335 339 <span type="species:ncbi:10090">mice</span>
###xml 358 362 <span type="species:ncbi:10090">mice</span>
###xml 447 451 <span type="species:ncbi:10090">mice</span>
###xml 716 720 <span type="species:ncbi:10090">mice</span>
The majority of GFP+ cells were located at the periphery of tumors and immunofluorescent visualization of the macrophage marker F4/80 indicated a good portion of these cells to be positive (33.6% in WT mice and 45.0% in DiYF mice; Fig. S3 A); however, the extent of perivascularly colocalized F4/80+ and GFP+ cells was low (6.1% in WT mice and 17.0% in DiYF mice; Fig. 5 B). Macrophage depletion with clodronate further reduced tumor size in DiYF mice (Fig. S3 E). Limited numbers of other hematopoietic cell types, such as granulocytes and monocytes (both are Gr-1 positive) and T-lymphocytes (CD3 positive) were located near the periphery of tumors but no obvious differences between DiYF/GFP-->WT and WT/GFP-->WT mice were found. By using a combination of anti-CD45, -F4/80, -CD3, and -Gr-1 antibodies for immunofluorescence analysis, along with visualization of GFP, we found that >95% of GFP+ cells in B16F10 tumors and >97% in RM1 tumors were positive for at least one of these markers (Fig. 5 C). Hence, the majority of BMD tumor-infiltrating cells were of hematopoietic origin.
###end p 33
###begin title 34
###xml 96 97 96 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 53 57 <span type="species:ncbi:10090">mice</span>
Reduced SDF-1 concentration in tumor tissues of DiYF mice leads to impaired recruitment of CXCR4+ BMDCs
###end title 34
###begin p 35
###xml 179 197 179 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">Kucia et al., 2005</xref>
###xml 199 217 199 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">Orimo et al., 2005</xref>
###xml 219 241 219 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Grunewald et al., 2006</xref>
###xml 685 693 673 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 952 960 940 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 B</xref>
###xml 459 463 <span type="species:ncbi:10090">mice</span>
###xml 539 543 <span type="species:ncbi:10090">mice</span>
###xml 631 635 <span type="species:ncbi:10090">mice</span>
###xml 679 683 <span type="species:ncbi:10090">mice</span>
###xml 834 838 <span type="species:ncbi:10090">mice</span>
###xml 898 902 <span type="species:ncbi:10090">mice</span>
A key factor for BMDC retention in angiogenic tissues is SDF-1, a chemokine produced by, but not limited to, mural cells such as perivascular fibroblasts and smooth muscle cells (Kucia et al., 2005; Orimo et al., 2005; Grunewald et al., 2006). DiYF angiogenic defects are accompanied by reduced numbers of SMA-positive cells, which may result in decreased levels of local and systemic SDF-1. Therefore, the SDF-1 content in tumors and plasma from WT and DiYF mice were determined. Although SDF-1 plasma levels in tumor-bearing WT and DiYF mice were closely matched (Fig. S4 A, available at ), tumor concentrations of SDF-1 in DiYF mice were approximately50% less than that of WT mice (Fig. 6 A). SDF-1 levels in leukocytes, BM cells, endothelial cell culture medium, and smooth muscle cell culture medium were similar for WT and DiYF mice (Fig. S4, B and C). Transplantation of WT marrow into DiYF mice normalized the levels of SDF-1 in tumor tissues (Fig. 6 B).
###end p 35
###begin p 36
###xml 0 57 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The SDF-1/CXCR4 axis regulates angiogenesis in DiYF mice.</bold>
###xml 163 164 161 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 179 180 177 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 361 362 357 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 663 664 656 657 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 664 665 657 658 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 675 676 668 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 774 775 767 768 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 867 868 858 859 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 920 921 911 912 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 925 926 913 914 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 926 927 914 915 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1005 1006 991 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 52 56 <span type="species:ncbi:10090">mice</span>
###xml 561 565 <span type="species:ncbi:10090">mice</span>
###xml 733 737 <span type="species:ncbi:10090">mice</span>
###xml 832 836 <span type="species:ncbi:10090">mice</span>
###xml 970 974 <span type="species:ncbi:10090">mice</span>
The SDF-1/CXCR4 axis regulates angiogenesis in DiYF mice. (A) Levels of SDF-1 in WT and DiYF B16F10 tumors. Data represent mean +/- SEM (duplicate measurements of n = 10 [WT] and n = 8 [DiYF] tumors each group). *, P < 0.05. (B) Levels of SDF-1 in WT and DiYF B16F10 tumors after BMT with WT donor marrow. Data represent mean +/- SEM (duplicate measurements of n = 6 per group). (C) Immunofluorescent detection of GFP (a, d, and g) and CXCR4 (b, e, and h) along with the merged image (c, f, and i). Sections are of RM1 origin in WT (a-c and g-i) and DiYF (d-f) mice after BMT with WT/GFP (a-f) or DiYF/GFP (g-i) donor marrow. (D) Peripheral blood analysis of beta3+ and CXCR4+ cells in nontumor- and B16F10 tumor-bearing WT and DiYF mice. (E) Percentage of circulating CXCR4+ cells in nontumor- and B16F10 tumor-bearing WT and DiYF mice. Data represent mean +/- SEM (n = 5 per group). (F) Percentage of circulating CXCR4+beta3+ cells in B16F10 tumor-bearing WT and DiYF mice. Data represent mean +/- SEM (n = 5 per group). **, P < 0.01.
###end p 36
###begin p 37
###xml 70 71 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 107 123 107 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">Jin et al., 2006</xref>
###xml 213 214 213 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 265 273 265 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 C</xref>
###xml 299 305 299 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 359 360 359 360 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 459 467 459 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 C</xref>
###xml 550 551 550 551 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 556 557 556 557 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 748 749 748 749 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1031 1032 1031 1032 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1075 1076 1060 1061 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1087 1095 1072 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 D</xref>
###xml 1129 1130 1114 1115 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1191 1199 1176 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 E</xref>
###xml 1260 1261 1245 1246 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1346 1347 1331 1332 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1447 1448 1429 1430 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1463 1464 1445 1446 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1573 1581 1555 1563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 F</xref>
###xml 1673 1674 1655 1656 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1681 1682 1663 1664 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1691 1692 1673 1674 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 812 816 <span type="species:ncbi:10090">mice</span>
###xml 820 824 <span type="species:ncbi:10090">mice</span>
###xml 1307 1311 <span type="species:ncbi:10090">mice</span>
###xml 1419 1423 <span type="species:ncbi:10090">mice</span>
###xml 1479 1483 <span type="species:ncbi:10090">mice</span>
###xml 1531 1535 <span type="species:ncbi:10090">mice</span>
###xml 1567 1571 <span type="species:ncbi:10090">mice</span>
###xml 1636 1640 <span type="species:ncbi:10090">mice</span>
###xml 1740 1744 <span type="species:ncbi:10090">mice</span>
###xml 1859 1863 <span type="species:ncbi:10090">mice</span>
SDF-1 has been shown to mediate the recruitment and retention of CXCR4+ BMDCs to angiogenic blood vessels (Jin et al., 2006). Immunohistochemical staining of tumor tissues for CXCR4 showed that the majority of GFP+ cells in tumor sections were also CXCR4 positive (Fig. 6 C). As noted previously in Fig. 5, there was an apparent defect in recruitment of CXCR4+ cells to tumor tissues of animals with DiYF but not WT BM regardless of the host tissue genotype (Fig. 6 C). To ensure that the discrepancy between apparent quantities of tumor resident GFP+CXCR4+ cells was not caused by variations in systemic availability of transplant groups, FACS analysis including differential blood cell counts was used to determine the levels of circulating CXCR4+ cells as well as cell populations in the blood of WT and DiYF mice or mice with implanted tumors. Our data showed no significant differences in circulating cell populations (Fig. S4, D and E) except for those expressing CXCR4. Approximately 10% of circulating leukocytes were CXCR4+. Of these, approximately30% expressed beta3 integrin (Fig. 6 D). The amount of circulating CXCR4+ cells in DiYF blood was marginally higher than in WT blood (Fig. 6 E). The presence of tumors almost doubled the amounts of CXCR4+ cells in the circulation of both WT and DiYF mice. Although the percentages of CXCR4+ cells in DiYF and WT blood were slightly different in nontumor-bearing mice, the percentage of beta3-positive CXCR4+ cells in DiYF mice was significantly higher in DiYF tumor-bearing mice compared with WT tumor-bearing mice (Fig. 6 F). Analysis of cells flushed from bones of WT and DiYF mice indicated no differences in CD34+, CXCR4+, or Sca1+ cell quantities in nontumor- and tumor-bearing mice (Fig. S4 F). These data indicate that the release of BMDCs into the circulation is normal or above normal in DiYF mice and, therefore, does not account for the observed defects in BMDC recruitment to sites of neovascularization and alludes to potential retention deficiencies of recruited DiYF BMDCs.
###end p 37
###begin p 38
###xml 122 142 122 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">Heissig et al., 2002</xref>
###xml 144 163 144 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">Kollet et al., 2006</xref>
###xml 165 183 165 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">Cheng et al., 2007</xref>
###xml 280 284 <span type="species:ncbi:10090">mice</span>
###xml 400 404 <span type="species:ncbi:10090">mice</span>
###xml 670 674 <span type="species:ncbi:10090">mice</span>
###xml 760 764 <span type="species:ncbi:10090">mice</span>
Other parameters such as MMP-2 and MMP-9 as well as osteoclast activity are known to influence BMDC mobilization in vivo (Heissig et al., 2002; Kollet et al., 2006; Cheng et al., 2007). We found elevated levels of total and active MMP-2 and MMP-9 in BM aspirates from WT and DiYF mice bearing tumors compared with nontumor-bearing counterparts; however, there were no differences between WT and DiYF mice not bearing or bearing tumors (Fig. S5, A and B, available at ). Moreover, osteoclast activity as determined by circulating levels of bone-specific tartrate-resistant acid phosphatase (TRAcP) 5b were found to be similar between WT and DiYF animals in tumor-bearing mice (Fig. S5 C). As such, the impaired accumulation of BMDCs at angiogenic sites in DiYF mice is not a consequence of defects in their release from BM.
###end p 38
###begin p 39
###xml 125 126 122 123 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 252 253 246 247 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 213 217 <span type="species:ncbi:10090">mice</span>
Collectively, these data emphasize the importance of the SDF-1/CXCR4 axis in BMDC recruitment and the importance of BMDC beta3 integrin function in this process. As mobilization of BMDCs is similar in WT and DiYF mice, it is easy to speculate that beta3 integrin on BM cells is crucial to recruitment processes after mobilization such as transendothelial migration and retention of recruited cells.
###end p 39
###begin title 40
###xml 4 5 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 78 79 75 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
beta3 function is crucial for adhesion and endothelial transmigration of CXCR4+ cells
###end title 40
###begin p 41
###xml 170 182 170 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">Mackay, 1995</xref>
###xml 230 231 227 228 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 295 296 292 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 400 401 397 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 636 637 633 634 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 707 708 704 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 716 724 713 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 A</xref>
###xml 747 748 744 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 851 852 848 849 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 860 868 857 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 B</xref>
###xml 888 889 885 886 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1055 1056 1052 1053 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1134 1135 1128 1129 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1244 1245 1238 1239 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 459 463 <span type="species:ncbi:10090">mice</span>
Many integrins are known to control cellular adhesion and transmigration through endothelium, which, in turn, controls lymphocyte homing and subsequent immune responses (Mackay, 1995). It is possible that the DiYF mutation of beta3 integrins could affect adhesion of circulating BM-derived CXCR4+ cells to the endothelial lining as well as their transmigration. To investigate this possibility, CXCR4+ cells were isolated from peripheral blood of WT and DiYF mice and their ability to adhere and transmigrate through an endothelial monolayer was assessed. The presence of tumors promoted a threefold increase in the adhesion of WT CXCR4+ cells to endothelium but had no effect on the adherence of DiYF CXCR4+ cells (Fig. 7 A). Likewise, DiYF CXCR4+ cells had an impaired ability to transmigrate through the endothelial monolayer compared with WT CXCR4+ cells (Fig. 7 B). However, WT CXCR4+ cell migration was twofold that of DiYF cells without tumor and increased in the presence of tumor, whereas the presence of tumor had no notable effect on DiYF CXCR4+ cell migration. These data illustrate the importance of fully functional beta3 integrin signaling in processes associated with recruitment into and retention of recruited BM-derived CXCR4+ cells at angiogenic sites.
###end p 41
###begin p 42
###xml 17 18 17 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 103 0 103 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Circulating CXCR4<sup>+</sup> cells from DiYF mice exhibit impaired adhesion to and migration through endothelium.</bold>
###xml 141 142 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 417 418 415 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 35 39 <span type="species:ncbi:10090">mice</span>
Circulating CXCR4+ cells from DiYF mice exhibit impaired adhesion to and migration through endothelium. (A) Relative number of adherent CXCR4+ cells from the peripheral blood of nontumor- and B16F10 tumor-bearing WT and DiYF after plating on an endothelial monolayer. Data represent mean +/- SEM and are representative of nine independent experiments. (B) Relative number of endothelial monolayer transmigrating CXCR4+ cells from the peripheral blood of nontumor- and B16F10 tumor-bearing WT and DiYF after plating on an endothelial monolayer. Data represent mean +/- SEM and are representative of five independent experiments. **, P < 0.01.
###end p 42
###begin title 43
Discussion
###end title 43
###begin p 44
###xml 47 48 44 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 195 221 192 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">Mahabeleshwar et al., 2006</xref>
###xml 435 441 432 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8</xref>
###xml 577 578 571 572 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1172 1173 1163 1164 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1282 1283 1273 1274 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1427 1428 1415 1416 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1467 1468 1455 1456 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1488 1489 1473 1474 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
###xml 376 380 <span type="species:ncbi:10090">mice</span>
###xml 750 754 <span type="species:ncbi:10090">mice</span>
###xml 1106 1110 <span type="species:ncbi:10090">mice</span>
Our previous studies showed that defective beta3 integrin signaling in DiYF mice resulted in inhibition of tumor growth and angiogenesis in vivo and impaired endothelial cell responses in vitro (Mahabeleshwar et al., 2006). The present study was initiated as a result of a preliminary finding wherein transplantation of WT BM completely rescued defective angiogenesis in DiYF mice. The findings presented in this paper are depicted in Fig. 8 with the key points summarized as follows. The course of tumor- and wound-associated angiogenic responses are dependent on BM cell beta3 integrin function and not resident host tissue. Defects in platelet function stemming from the DiYF mutation are not causative of the angiogenic defects displayed by DiYF mice. The recruitment of DiYF BMDCs to sites of neovascularization is compromised compared with that of WT BMDCs. The majority of recruited BMDCs are negative for endothelial or smooth muscle cell markers, but appear to express CD45, Gr1, CD3, and CXCR4, indicating the hematopoietic origin of these cells. SDF-1 levels are reduced in tumors grown in DiYF mice compared with WT, a condition corrected by BMT. Impaired beta3 integrin activity has little effect on the process of BMDC release into the circulation; however, DiYF CXCR4+ BMDCs exhibit defective adhesion and transmigration through endothelial monolayers compared with WT counterparts. These data indicate that beta3 integrin activity on circulating CXCR4+ BMDCs, but not beta3 integrin on resident endothelial cells or platelets, plays a governing role in angiogenesis through regulating BMDC recruitment to angiogenic sites and adherence to and transmigration through endothelium.
###end p 44
###begin p 45
###xml 74 75 71 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 0 118 0 115 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Model depicting steps in the angiogenic process affected by defective &#946;<sub>3</sub> integrin as exemplified by the DiYF mouse.</bold>
###xml 141 142 135 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 406 407 400 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 713 714 707 708 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 112 117 <span type="species:ncbi:10090">mouse</span>
###xml 164 169 <span type="species:ncbi:10090">mouse</span>
###xml 536 540 <span type="species:ncbi:10090">mice</span>
Model depicting steps in the angiogenic process affected by defective beta3 integrin as exemplified by the DiYF mouse. Although impaired beta3 function in the DiYF mouse does not affect the mobilization of BMDCs from the BM niche, it weakens adhesion and decreases migration functions, which, in turn, reduce the overall recruitment and retention of BMDCs, resulting in elevated levels of circulating CXCR4+ BMDCs. This leads to dampened vascular sprouting and an inhibition of angiogenesis. Defective endothelial cell function in DiYF mice appears to play a recessive role in this process. Low levels of SDF-1, a result of this angiogenic defect, further potentiate the reduced recruitment and retention of CXCR4+ cells.
###end p 45
###begin p 46
###xml 26 27 23 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 119 120 113 114 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 208 209 198 199 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 213 214 200 201 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 259 279 246 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">Brooks et al., 1994a</xref>
###xml 280 281 267 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">b</xref>
###xml 302 303 286 287 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 369 390 353 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">Reynolds et al., 2002</xref>
###xml 464 465 445 446 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 539 559 520 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib51">Taverna et al., 2004</xref>
###xml 741 742 719 720 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 827 828 801 802 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 832 833 803 804 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 921 922 889 890 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 313 317 <span type="species:ncbi:10090">mice</span>
###xml 471 475 <span type="species:ncbi:10090">mice</span>
###xml 696 700 <span type="species:ncbi:10090">mice</span>
###xml 932 936 <span type="species:ncbi:10090">mice</span>
A definitive role for beta3 integrin in the regulation of angiogenesis remains elusive. Conflicting data regarding beta3 integrin's role in the development of neovasculature have been reported. Although alphavbeta3 inhibitors define a proangiogenic function (Brooks et al., 1994a,b), studies using beta3 knockout mice suggest negative regulatory angiogenic properties (Reynolds et al., 2002). Interestingly, increased tumor vascularization and tumor growth in beta3-null mice could be reversed by marrow repopulation with WT donor marrow (Taverna et al., 2004), thus implicating BM as a key factor in the neovascularization processes. Although the impaired angiogenesis exhibited by DiYF knockin mice alludes to a proangiogenic role for beta3 integrin in angiogenic responses similar to that described using inhibitors of alphavbeta3, this impairment can be rescued through BMT with WT marrow, a response mirrored in beta3 knockout mice.
###end p 46
###begin p 47
###xml 26 27 23 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 226 227 220 221 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 287 290 277 280 <sub xmlns:xlink="http://www.w3.org/1999/xlink">IIb</sub>
###xml 294 295 281 282 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 397 400 380 383 <sub xmlns:xlink="http://www.w3.org/1999/xlink">IIb</sub>
###xml 404 405 384 385 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 521 539 501 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">Brill et al., 2004</xref>
###xml 541 562 521 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">Italiano et al., 2007</xref>
###xml 672 675 648 651 <sub xmlns:xlink="http://www.w3.org/1999/xlink">IIb</sub>
###xml 679 680 652 653 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 806 823 779 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">Rhee et al., 2004</xref>
###xml 1422 1425 1391 1394 <sub xmlns:xlink="http://www.w3.org/1999/xlink">IIb</sub>
###xml 1429 1430 1395 1396 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1523 1541 1489 1507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">Brill et al., 2004</xref>
###xml 1543 1563 1509 1529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">Kisucka et al., 2006</xref>
###xml 521 526 <span type="species:ncbi:65125">Brill</span>
###xml 777 782 <span type="species:ncbi:10090">mouse</span>
###xml 886 890 <span type="species:ncbi:10090">mice</span>
###xml 1131 1135 <span type="species:ncbi:10090">mice</span>
###xml 1267 1271 <span type="species:ncbi:10090">mice</span>
###xml 1523 1528 <span type="species:ncbi:65125">Brill</span>
###xml 1585 1589 <span type="species:ncbi:10090">mice</span>
Thus, results of both beta3 knockin and knockout models suggest pathological angiogenesis is dependent on the function of this integrin on BM cells rather than residential endothelium. Because both knockout and knockin of beta3 integrin are known to affect the function of platelet alphaIIbbeta3, an obvious explanation for the results of BMT studies would be the regulatory role of platelet alphaIIbbeta3 in angiogenesis. Indeed, platelets were recently shown to regulate pathological vascularization in certain models (Brill et al., 2004; Italiano et al., 2007). In addition, thrombocytopenia, as well as the inhibition of platelet aggregation by a highly specific alphaIIbbeta3 integrin antagonist, resulted in a reduction of retinal neovascularization in a hypoxia-induced mouse model of angiogenesis (Rhee et al., 2004). Considering these data, impaired platelet functions of DiYF mice should elicit angiogenic defects and stunted tumor growth, both of which should be capable of being abrogated or reduced through the depletion of circulating platelets. Platelet depletion reduced the angiogenic response in both WT and DiYF mice; however, the absence of circulating platelets failed to normalize the angiogenic and tumor growth differences between WT and DiYF mice. Thus, it appears that platelets are not solely responsible for the effects of BMT. This finding is in agreement with prior work suggesting that alphaIIbbeta3 inhibitors fail to modify blood vessel development or platelet-tumor interactions in vitro (Brill et al., 2004; Kisucka et al., 2006). Therefore, in DiYF mice there is a functional defect in other types of BMDCs that substantially contribute to the angiogenic phenotype.
###end p 47
###begin p 48
###xml 226 247 226 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">De Palma et al., 2005</xref>
###xml 249 267 249 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">Orimo et al., 2005</xref>
###xml 269 291 269 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Grunewald et al., 2006</xref>
###xml 533 551 533 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">Lyden et al., 2001</xref>
###xml 553 572 553 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">Peters et al., 2005</xref>
###xml 646 667 646 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">De Palma et al., 2005</xref>
###xml 669 691 669 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Grunewald et al., 2006</xref>
###xml 870 896 870 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib58">Ziegelhoeffer et al., 2004</xref>
###xml 1329 1355 1329 1355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib58">Ziegelhoeffer et al., 2004</xref>
###xml 1357 1379 1357 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Grunewald et al., 2006</xref>
###xml 1381 1397 1381 1397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">Jin et al., 2006</xref>
###xml 1436 1458 1436 1458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Grunewald et al., 2006</xref>
###xml 1734 1735 1731 1732 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 52 56 <span type="species:ncbi:10090">mice</span>
###xml 374 378 <span type="species:ncbi:10090">mice</span>
Our results using BMT of GFP-expressing WT and DiYF mice revealed recruitment deficiencies of DiYF BMDCs in comparison to WT BMDCs. Several recent studies have demonstrated stimulatory roles for BMDCs in angiogenic processes (De Palma et al., 2005; Orimo et al., 2005; Grunewald et al., 2006), potentially explaining the overall reduced angiogenic response observed in DiYF mice. These reports define distinctly different roles of BMDCs in angiogenesis with some purporting direct incorporation of BMDCs into developing vasculature (Lyden et al., 2001; Peters et al., 2005), whereas others illustrate a supporting, paracrine role of these BMDCs (De Palma et al., 2005; Grunewald et al., 2006). In our model, BMDCs were found to be adjacent to endothelial cells or to SMA-positive pericytes and outside of the laminin basement membrane, similar to the reports of others (Ziegelhoeffer et al., 2004). With little to no recruited BMDCs displaying endothelial or pericyte characteristics, results from our model suggest a more supporting, paracrine-like function of BMDCs in angiogenesis. At the same time, we observed that the majority of recruited BMDCs appear to be of hematopoietic origin as they express CD45, F4/80, CD3, and Gr1. Similar papers by others emphasize the role of hematopoietic cells in angiogenic in vivo models (Ziegelhoeffer et al., 2004; Grunewald et al., 2006; Jin et al., 2006). In addition, we, along with others (Grunewald et al., 2006), have found that CXCR4 appears to be a marker expressed on the vast majority of recruited BMDCs. Therefore, in our model, BMDCs have a prominent stimulatory role in neovascularization without direct incorporation into blood vessels. Moreover, the functional activity of beta3 integrin on BMDCs is crucial for their recruitment.
###end p 48
###begin p 49
###xml 75 97 75 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">Lindbom and Werr, 2002</xref>
###xml 99 121 99 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Grunewald et al., 2006</xref>
###xml 123 148 123 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">Lamagna and Bergers, 2006</xref>
###xml 150 165 150 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib53">Vestweber, 2007</xref>
###xml 213 214 210 211 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 409 429 406 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">Hattori et al., 2002</xref>
###xml 431 453 428 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">Lindbom and Werr, 2002</xref>
###xml 455 477 452 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Grunewald et al., 2006</xref>
###xml 479 496 476 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">Kopp et al., 2006</xref>
###xml 503 504 497 498 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 566 583 560 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib57">Zhao et al., 2005</xref>
###xml 668 687 662 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">Kollet et al., 2006</xref>
###xml 729 747 723 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib57">Zhao et al. (2005)</xref>
###xml 899 900 890 891 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1008 1009 999 1000 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1054 1055 1042 1043 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1106 1107 1094 1095 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1441 1463 1429 1451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">Lindbom and Werr, 2002</xref>
###xml 1465 1486 1453 1474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib48">Schenkel et al., 2004</xref>
###xml 1488 1507 1476 1495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">Millan et al., 2006</xref>
###xml 1652 1653 1636 1637 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 1657 1658 1638 1639 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1709 1729 1690 1710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">Buckley et al., 1996</xref>
###xml 1840 1862 1821 1843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">Lindbom and Werr, 2002</xref>
###xml 1880 1881 1857 1858 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 1885 1886 1859 1860 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 2046 2070 2020 2044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib54">Weerasinghe et al., 1998</xref>
###xml 2072 2094 2046 2068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">Lindbom and Werr, 2002</xref>
###xml 2205 2231 2179 2205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">Mahabeleshwar et al., 2006</xref>
###xml 2317 2318 2291 2292 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2427 2428 2398 2399 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 839 843 <span type="species:ncbi:10090">mice</span>
###xml 958 962 <span type="species:ncbi:10090">mice</span>
Because BMDC recruitment to neovascularizing sites is a multistep process (Lindbom and Werr, 2002; Grunewald et al., 2006; Lamagna and Bergers, 2006; Vestweber, 2007), we assessed whether impaired activity of beta3 integrin influences the process of BMDC release from the BM niche into the circulation. The latter process is known to be triggered by angiogenic factors produced by injured tissues and tumors (Hattori et al., 2002; Lindbom and Werr, 2002; Grunewald et al., 2006; Kopp et al., 2006). beta3 integrin is crucial for osteoclast-mediated bone resorption (Zhao et al., 2005), which, in turn, contributes to the release of cells from the BM niche into blood (Kollet et al., 2006). However, similar to the experiments by Zhao et al. (2005), we observed no major differences in bone resorptive function of tumor-bearing WT and DiYF mice, indicating that the DiYF mutation does not impair beta3 integrin activity on osteoclasts. Thus, even though DiYF mice exhibited higher numbers of circulating CXCR4+ BMDCs compared with WT, it appears that beta3 integrin activity affects not the release of CXCR4+ cells from BM, but rather their recruitment from the circulation into tissues. Vascular walls present a barrier to circulating cells for relocating from the blood stream to sites of angiogenesis. The recruitment of BMDCs into surrounding tissues involves sequential interactions with endothelium and extravascular tissue components (Lindbom and Werr, 2002; Schenkel et al., 2004; Millan et al., 2006). First, transmigrating BMDCs need to establish transient and dynamic adhesive contacts with endothelium. Previous studies have shown that alphavbeta3 integrin serves as a heterotypic ligand for CD31 (Buckley et al., 1996), a molecular marker for endothelial cells, and controls the arrest and extravasation of hematopoietic cells (Lindbom and Werr, 2002). Moreover, alphavbeta3 integrin on monocytes, neutrophils, and other leukocyte subsets plays a key role in the transition between tight adhesion to the VE and subsequent diapedesis (Weerasinghe et al., 1998; Lindbom and Werr, 2002). Our previous study demonstrated that the DiYF mutation impairs adhesion and migration of endothelial cells (Mahabeleshwar et al., 2006). In this study, we found that this mutation affected the ability of BM-derived CXCR4+ cells to adhere to and transmigrate through an endothelial monolayer. Therefore, functional activity of beta3 integrin is crucial for the adhesion and transmigration of BMDCs at sites of neovascularization, which, in turn, is crucial for the angiogenesis-dependent responses of tumor growth and wound healing.
###end p 49
###begin p 50
###xml 97 98 97 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 124 144 124 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">Hattori et al., 2002</xref>
###xml 146 168 146 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">Hiratsuka et al., 2002</xref>
###xml 170 192 170 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Grunewald et al., 2006</xref>
###xml 194 211 194 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">Kopp et al., 2006</xref>
###xml 250 251 250 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 523 541 523 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">Petit et al., 2007</xref>
###xml 588 589 588 589 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 707 725 707 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">Petit et al., 2007</xref>
###xml 809 825 809 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">Ara et al., 2005</xref>
###xml 1013 1014 1013 1014 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1034 1054 1034 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">Hattori et al., 2001</xref>
###xml 1056 1076 1056 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">Heissig et al., 2002</xref>
###xml 1375 1376 1375 1376 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1385 1386 1385 1386 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1390 1391 1387 1388 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1391 1392 1388 1389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1634 1635 1631 1632 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1698 1699 1695 1696 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1708 1709 1705 1706 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1713 1714 1707 1708 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1714 1715 1708 1709 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1729 1730 1720 1721 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 2030 2048 2021 2039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">Fedyk et al., 2001</xref>
###xml 2050 2068 2041 2059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">Orimo et al., 2005</xref>
###xml 2070 2087 2061 2078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">Ruiz et al., 2006</xref>
###xml 324 328 <span type="species:ncbi:10090">mice</span>
###xml 360 364 <span type="species:ncbi:10090">mice</span>
###xml 1156 1160 <span type="species:ncbi:10090">mice</span>
###xml 1339 1343 <span type="species:ncbi:10090">mice</span>
###xml 1450 1454 <span type="species:ncbi:10090">mice</span>
###xml 1492 1496 <span type="species:ncbi:10090">mice</span>
###xml 1777 1781 <span type="species:ncbi:10090">mice</span>
###xml 1852 1856 <span type="species:ncbi:10090">mice</span>
###xml 1890 1894 <span type="species:ncbi:10090">mice</span>
###xml 2277 2281 <span type="species:ncbi:10090">mice</span>
###xml 2364 2368 <span type="species:ncbi:10090">mice</span>
Angiogenic factors released by peripheral tissues promote mobilization of BMDCs, especially CXCR4+ cells from the BM niche (Hattori et al., 2002; Hiratsuka et al., 2002; Grunewald et al., 2006; Kopp et al., 2006). Indeed, our data showed higher CXCR4+ cell numbers in the circulating blood of both tumor-bearing WT and DiYF mice compared with nontumor-bearing mice. SDF-1, along with its receptor CXCR4, is a key chemoattractant for hematopoietic progenitor/stem cell mobilization, trafficking, recruitment, and retention (Petit et al., 2007). As perivascular cells, these recruited CXCR4+ hematopoietic cells promote and stabilize neovessels by releasing angiogenic factors and providing physical support (Petit et al., 2007). In fact, defective vascularization was noted in SDF-1 or CXCR4 knockout embryos (Ara et al., 2005). In our model, all of the vasculature-associated BMDCs were CXCR4 positive, indicating that these cells were recruited by its ligand, SDF-1. Elevated plasma SDF-1 levels stimulates CXCR4+ BMDC mobilization (Hattori et al., 2001; Heissig et al., 2002). We did not find any notable differences in plasma SDF-1 levels in WT or DiYF mice. Other factors associated with BMDC mobilization and osteoclast function, such as BM resident MMP-2 and MMP-9 or serum TRAcP levels, were also found to be similar in WT and DiYF mice. However, increased blood CXCR4+ or CXCR4+beta3+ cell numbers were observed in DiYF or tumor-bearing DiYF mice compared with WT or tumor-bearing WT mice. Therefore, decreased recruitment of BMDCs into tissues and defective adhesive and migratory capacities and hence retention of DiYF CXCR4+ BMDCs were causal in the increased levels of circulating CXCR4+ or CXCR4+beta3+ cells in beta3 integrin-defective DiYF or tumor-bearing DiYF mice. Interestingly, we found that the levels of SDF-1 in tumors from DiYF mice were lower than tumor-bearing WT mice. The major source of SDF-1 in peripheral tissues are VE cells, epithelial cells, stromal fibroblasts, and SMA-positive myofibroblasts (Fedyk et al., 2001; Orimo et al., 2005; Ruiz et al., 2006). Thus, in our model, defective recruitment of BMDCs and impaired angiogenesis were accompanied by reduced SDF-1 expression, which, in turn, further augmented the angiogenic defect in DiYF mice. Transplantation of WT BM restored these defects, including SDF-1 levels, in DiYF mice.
###end p 50
###begin p 51
###xml 50 51 47 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 191 192 184 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 196 197 186 187 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
In sum, this study establishes a new role for beta3 integrin in the regulation of angiogenesis, one that may influence not only the interpretations of numerous preclinical studies using alphavbeta3 inhibitors but also the development of new anti- as well as proangiogenic strategies.
###end p 51
###begin title 52
Materials and methods
###end title 52
###begin title 53
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 53
###begin p 54
###xml 82 98 82 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">Law et al., 1999</xref>
###xml 23 27 <span type="species:ncbi:10090">mice</span>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
###xml 166 170 <span type="species:ncbi:10090">mice</span>
###xml 212 216 <span type="species:ncbi:10090">mice</span>
8-12-wk-old WT or DiYF mice were on a C57BL/6 background as described previously (Law et al., 1999). WT/GFP mice were purchased from The Jackson Laboratory. DiYF/GFP mice were bred from DiYF and GFP heterozygote mice. All animal procedures were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of the Cleveland Clinic.
###end p 54
###begin title 55
Subcutaneous tumor and wound healing models
###end title 55
###begin p 56
###xml 41 42 41 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 88 105 88 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">Chen et al., 2005</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
###xml 197 201 <span type="species:ncbi:10090">mice</span>
###xml 239 243 <span type="species:ncbi:10090">mice</span>
Mice were injected subcutaneously with 106 B16F10 melanoma or RM1 prostate tumor cells (Chen et al., 2005). Tumors were harvested 9 (RM1 in WT and DiYF mice), 11 (B16F10 and RM1 in BMT WT and DiYF mice), or 13 d (B16F10 in BMT WT and DiYF mice) after implantation, weighed, and processed for histological and immunohistochemical staining.
###end p 56
###begin p 57
###xml 66 86 66 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">Hoffman et al., 2006</xref>
A back punch wound healing model was used as described elsewhere (Hoffman et al., 2006). Digital photographs were taken at the time of injury and on days 3, 7, 10, and 13 thereafter. Pictures were taken using a microscope (SMZ 1000; Nikon) equipped with a digital camera (DXM1200F; Nikon). The wound area was analyzed by tracing the wound margin from images and calculating pixel area with ImagePro Plus software (v5.1; Media Cybernetics). Wound healing area was calculated as a percentage of area of the original wound.
###end p 57
###begin p 58
###xml 127 128 127 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 17 21 <span type="species:ncbi:10090">mice</span>
###xml 186 190 <span type="species:ncbi:10090">mice</span>
For BMT studies, mice (recipients) were lethally irradiated (9 Gy) followed by BM reconstitution by tail vein injection with 107 BM cells isolated from the donor femurs. 8 wk after BMT, mice were used for tumor or wound healing experiments.
###end p 58
###begin title 59
Platelet depletion and tumor implantation
###end title 59
###begin p 60
###xml 41 42 41 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 197 200 <span type="species:ncbi:10116">rat</span>
###xml 206 211 <span type="species:ncbi:10090">mouse</span>
###xml 277 280 <span type="species:ncbi:10116">rat</span>
Mice were injected subcutaneously with 106 B16F10 tumor cells and then randomly grouped into two groups. 30 min after tumor implantation, the experimental group received an intravenous infusion of rat anti-mouse GPIbalpha (Emfret Analytics), whereas the control group received rat IgG (both at 2 mug/g of body weight) in 200 mul of sterile PBS. Injections of antibodies were repeated on days 3 and 6 to maintain low platelet counts. Platelet numbers in circulating blood were monitored using tail vein blood. Tumors were removed and analyzed on day 9.
###end p 60
###begin title 61
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
Murine SDF-1 immunoassay
###end title 61
###begin p 62
###xml 22 27 <span type="species:ncbi:10090">mouse</span>
SDF-1alpha content in mouse plasma or tumor lysate was determined by an SDF-1 ELISA kit (R&D Systems). ELISA was performed using ELISA Kinetic microplate reader (MDS Analytical Technologies). Total protein content was quantified by Bradford assay to equalize protein loading.
###end p 62
###begin title 63
Flow cytometry
###end title 63
###begin p 64
###xml 130 131 130 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 237 238 237 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 374 375 371 372 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 588 589 582 583 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 53 58 <span type="species:ncbi:10090">mouse</span>
###xml 175 178 <span type="species:ncbi:10116">rat</span>
###xml 184 189 <span type="species:ncbi:10090">mouse</span>
###xml 336 341 <span type="species:ncbi:10090">mouse</span>
###xml 352 358 <span type="species:ncbi:9986">rabbit</span>
###xml 364 369 <span type="species:ncbi:9606">human</span>
###xml 471 475 <span type="species:ncbi:9925">goat</span>
###xml 481 487 <span type="species:ncbi:9986">rabbit</span>
Erythrocytes were removed from blood samples using a mouse erythrocyte lysing kit (R&D Systems). The remaining cell population (106) was stained with phycoerythrin-conjugated rat anti-mouse CXCR4 antibody (R&D Systems) to determine CXCR4+ cell quantities. Alternatively, double staining was performed with phycoerythrin-conjugated anti-mouse CXCR4 and rabbit anti-human beta3 integrin as primary antibodies (Santa Cruz Biotechnology, Inc.) and Alexa Fluor 488-conjugated goat anti-rabbit IgG as the secondary antibody. Cells were permeabilized with 0.2% Triton X-100 for 5 min before beta3 integrin staining. FACS analyses were performed using FACSCalibur and data were analyzed using CellQuest Software (version 3.8; BD).
###end p 64
###begin title 65
Adhesion and transmigration of BMDCs
###end title 65
###begin p 66
###xml 159 160 159 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 323 349 323 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">Mahabeleshwar et al., 2006</xref>
###xml 484 485 484 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 495 496 495 496 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 631 632 625 626 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1061 1062 1055 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i</italic>
###xml 86 91 <span type="species:ncbi:10090">mouse</span>
###xml 270 275 <span type="species:ncbi:10090">mouse</span>
Peripheral blood cells were isolated and stained with a phycoerythrin-conjugated anti-mouse CXCR4 antibody and sorted with a FACSVantage SE station (BD). CXCR4+ cells were collected and further stained with FAST DiI (Invitrogen). Endothelial cells were isolated from WT mouse lung microvasculature as described previously (Mahabeleshwar et al., 2006) and cultured as monolayers on fibronectin-coated plates or in the upper chamber of a Boyden-type migration chamber. DiI-stained CXCR4+ BMDCs (104) were added on top of endothelial monolayers and incubated for 1 (adhesion) or 18 h (transmigration) at 37degreesC in humidified 5% CO2 air. Dishes of adherent cells were fixed with 4% paraformaldehyde, washed, and photographed with an inverted fluorescence microscope (DMIRB; Leica). Numbers of DiI-positive attached and spread cells on the endothelial cell monolayer were counted. Alternatively, transmigrated cells in the lower chamber of the migration chamber were collected and counted with an inverted fluorescent microscope equipped with a camera (Retiga EXi; QImaging).
###end p 66
###begin title 67
Histology and immunohistochemistry
###end title 67
###begin p 68
###xml 207 224 207 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">Chen et al., 2005</xref>
###xml 1297 1298 1293 1294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i</italic>
###xml 1433 1450 1429 1446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">Chen et al., 2005</xref>
###xml 271 274 <span type="species:ncbi:10116">rat</span>
###xml 280 285 <span type="species:ncbi:10090">mouse</span>
###xml 320 323 <span type="species:ncbi:10116">rat</span>
###xml 329 334 <span type="species:ncbi:10090">mouse</span>
###xml 356 359 <span type="species:ncbi:10116">rat</span>
###xml 365 370 <span type="species:ncbi:10090">mouse</span>
###xml 413 416 <span type="species:ncbi:10116">rat</span>
###xml 422 427 <span type="species:ncbi:10090">mouse</span>
###xml 449 455 <span type="species:ncbi:9986">rabbit</span>
###xml 478 484 <span type="species:ncbi:9986">rabbit</span>
###xml 511 517 <span type="species:ncbi:9986">rabbit</span>
###xml 548 551 <span type="species:ncbi:10116">rat</span>
###xml 557 562 <span type="species:ncbi:10090">mouse</span>
###xml 574 580 <span type="species:ncbi:9986">rabbit</span>
###xml 586 590 <span type="species:ncbi:9925">goat</span>
###xml 641 644 <span type="species:ncbi:10116">rat</span>
###xml 650 655 <span type="species:ncbi:10090">mouse</span>
###xml 731 737 <span type="species:ncbi:9986">rabbit</span>
###xml 759 765 <span type="species:ncbi:9986">rabbit</span>
Tissues were fixed with 4% paraformaldehyde and embedded in paraffin or in OCT freezing medium. Histological and immunohistochemical staining was performed using standard techniques as described previously (Chen et al., 2005). The following primary antibodies were used: rat anti-mouse CD31 (Research Diagnostics Inc.), rat anti-mouse F4/80 (AbD Serotec), rat anti-mouse Gr-1 (BD), Cy3-alpha-SMA (Sigma-Aldrich), rat anti-mouse CXCR4 (R&D Systems), rabbit anti-NG2 (Millipore), rabbit anti-GFP (AnaSpec, Inc.), rabbit anti-laminin (Sigma-Aldrich), rat anti-mouse CD45 (BD), rabbit anti-goat VE-Cadherin (Santa Cruz Biotechnology, Inc.), and rat anti-mouse CD3 (eBioscience). All antibodies were used at a 1:100 dilution except for rabbit anti-GFP (1:500) and rabbit anti-laminin (1:1,000). Chromogenic visualization followed the Vectastain ABC kit protocol (Vector Laboratories). Secondary antibodies fluorescently labeled with Alexa Fluor 488 or Alexa Fluor 594 (Invitrogen) were used for immunofluorescence at a 1:200 dilution. All the slides were mounted with Vectashield mounting medium with DAPI (Vector Laboratories). Specimens were photographed using a research microscope system (DMR; Leica) or a laser-scanning confocal microscope (DMRXE TCS SP2; Leica), equipped with a camera (Retiga EXi). Quantitative analysis of the positively stained area or density was performed using ImagePro Plus software as described previously (Chen et al., 2005).
###end p 68
###begin title 69
Western blot analysis
###end title 69
###begin p 70
###xml 374 375 374 375 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 376 377 376 377 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 378 379 378 379 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 72 76 <span type="species:ncbi:10090">mice</span>
BM cells were isolated by flushing the femurs and tibiae of WT and DiYF mice with ice-cold PBS. Cells were collected by centrifugation at 2,000 rpm for 5 min and lysed in buffer composed of 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 5 mM iodoacetamide, 2 mM phenylmethylsulfonyl fluoride, 2 mM EDTA, 10 mM NaF, 10 mM Na2P2O7, 10 mug/ml leupeptin, 4 mug/ml pepstatin, and 0.1 U/ml aprotinin. Cell lysates were cleared and supernatants were assayed for protein concentration using the Bradford protein assay method (Bio-Rad Laboratories). Cell lysates were denatured using Laemmli sample buffer, and proteins were separated by SDS-PAGE and then probed with the indicated antibody. Where appropriate, nitrocellulose membranes were stripped and blotted with anti-actin antibody as a loading control. Antibodies used were anti-MMP-2 and -MMP-9 (Santa Cruz Biotechnology, Inc.) and anti-beta-actin (Sigma-Aldrich).
###end p 70
###begin title 71
Measurement of MMP-2, MMP-9, and osteoclast activity
###end title 71
###begin p 72
###xml 120 124 <span type="species:ncbi:10090">mice</span>
###xml 328 332 <span type="species:ncbi:10090">mice</span>
BM resident MMP-2 and MMP-9 levels were assessed using BM aspirate lysates from nontumor- and tumor-bearing WT and DiYF mice. Protein content and assay volumes were equalized before using the measurement kit (R&D Systems). Osteoclast activity was measured by quantification of TRAcP 5b in the serum of tumor-bearing WT and DiYF mice using a commercially available ELISA kit (Immunodiagnostic Systems, Inc).
###end p 72
###begin title 73
Statistical analysis
###end title 73
###begin p 74
###xml 86 87 86 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
The statistical difference between groups was determined using a two-tailed Student's t test or analysis of variance. P-values of 0.05 or less were regarded as statistically significant.
###end p 74
###begin title 75
Online supplemental material
###end title 75
###begin p 76
###xml 90 91 87 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 170 171 164 165 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
###xml 287 291 <span type="species:ncbi:10090">mice</span>
###xml 380 384 <span type="species:ncbi:10090">mice</span>
###xml 480 484 <span type="species:ncbi:10090">mice</span>
###xml 546 550 <span type="species:ncbi:10090">mice</span>
Fig. S1 shows that decreased angiogenesis in DiYF mice is caused by impaired integrin beta3 activation in BMDCs. Fig. S2 shows that infiltration of BMDCs is integrin beta3 dependent. Fig. S3 shows the localization of F4/80-positive macrophages in a B16F10 tumor implanted in WT and DiYF mice transplanted with GFP-BM. Fig. S4 shows the SDF-1 levels in the plasma from WT and DiYF mice. Fig. S4 also shows the number of different types of circulating cells in blood in WT and DiYF mice. Fig. S5 shows MMP-2 and MMP-9 contents in BM in WT and DiYF mice with or without B16F10 tumors. Online supplemental material is available at .
###end p 76
###begin title 77
Supplementary Material
###end title 77
###begin title 78
[Supplemental Material Index]
###end title 78
###begin p 79
We acknowledge financial support from the National Institutes of Health (grants HL071625, CA126847, and HL073311).
###end p 79
###begin p 80
The authors have no conflicting financial interests.
###end p 80

